OakChart

Enveric Biosciences Inc

ENVBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:58 PM ET

1.49-0.02 (-1.32%)
2026-11-11 22:30 CET
Market cap
6.76 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-12.09 USD m
Free cash flow, TTM
-8.56 USD m
EPS diluted, TTM
-16.46
P/E
-
Compare

Price

ENVB against its 20, 50 and 200-day averages
2050200earnings
2.004.006.00904K1.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ENVBclose 1.4920-day 1.4450-day 1.46200-day 1.911.4952w low

88.8% under the 52-week high of 13.25 on 10 Dec 2025. 52-week low 1.17 on 26 Aug 2026. Last 15 sessions, 21.5% high to low

Volume 0.14× normal · the line is the 50-bar volume average

Profile

ENVB
52-week range, 3% of the way up
1.1713.25

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Employees6
IPOAug 22, 1995
Beta1.18
ATR, 14d0.10
Rel volume0.14
Short float0.45%
Insider own1.64%
Inst own15.88%

Snapshot

6 groups

Valuation

Index-
Market Cap6.67M
Enterprise Value-1.63M
Income-12.09M
Sales0.00M
Book/sh2.05
Cash/sh1.85
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPOAug 22, 1995

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.73
P/C0.80
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio10.21
Current Ratio10.21
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-16.46
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y75.07% 67.96%
Sales past 3/5Y- -
EPS Y/Y TTM87.05%
Sales Y/Y TTM-
EPS Q/Q93.48%
Sales Q/Q-
EarningsAug 14 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own1.64%
Insider Trans0.00%
Inst Own15.88%
Inst Trans8.92%
ROA-139.75%
ROE-170.04%
ROIC-108.00%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.46%
SMA501.76%
SMA200-22.05%
Trades-

Technical

Shs Outstand4.48M
Shs Float4.40M
Short Float0.45%
Short Ratio0.27
Short Interest0.02M
52W High13.25 -88.75%
52W Low1.17 27.34%
Volatility6.45% 7.24%
ATR (14)0.10
RSI (14)53.88
Beta1.18
Rel Volume0.14
Avg Volume72.59K
Volume10,182

Performance

Perf Week2.05%
Perf Month6.43%
Perf Quarter-1.32%
Perf Half Y-38.93%
Perf YTD-58.95%
Perf Year-74.92%
Perf 3Y-99.48%
Perf 5Y-99.99%
Perf 10Y-100.00%
Recom1.00
Target Price1800.00
Prev Close1.51
Price1.49
Change %-1.32%

Peers

Mkt cap
TickerCompanyMkt cap
CMNDClearmind Medicine Inc2.53M
PBMPsyence Biomedical Ltd12.13M
DRUGBright Minds Biosciences Inc231.32M
GHRSGH Research PLC1.32B
SILOSILO Pharma Inc2.92M
VTGNVistagen Therapeutics Inc8.34M
KTTAPasithea Therapeutics Corp17.77M
JUNSJupiter Neurosciences Inc2.82M
RLMDRelmada Therapeutics Inc472.55M
ANVSAnnovis Bio Inc36.41M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q42026-08-14-57.960-41.400-57.8020.000.001
2025Q42026-03-270.850--0.00--
2025Q32025-11-14-10.810--10.8130.00--
2025Q22025-08-14-11.640--11.6460.00--
2025Q12025-05-14-14.640--14.5840.00--
2024Q32024-11-14-43.200--43.1030.00--
2024Q22024-08-12-41.400-99.000-44.5820.000.001
2024Q12024-05-15-109.8-139.5-110.520.000.002
2023Q42024-03-26-262.8-284.4-263.310.000.003
2023Q32023-11-13-234-376.2-234.680.000.002
2023Q22023-08-14-547.2-117-546.580.00-1
2023Q12023-05-15-415.8--415.8---
2022Q32022-11-14-561.6-720-262.11--1
2022Q22022-08-12-540-675-476.640.000.002
2022Q12022-05-13-810-1,080-961.290.000.001
2021Q42022-03-31-1,350-1,440-11,6320.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-675,000-585,000-675,00048.5948.15
2018FY-738,000-27,000-736,97443.0041.31
2020FY-10,710--10,738--
2021FY-18,630-4,590-18,664-0.00
2022FY-2,340-2,601-2,340-0.00
2023FY-1,460-1,469-1,4560.000.00
2024FY-252.36-208.8-228.480.000.00
2025FY-36.240--0.00-
2026FY--315---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q3E2024-09-06100-5.25-5.25-5.25
2025Q3E2024-09-05100-5.25-5.25-5.25
2025Q3E2024-09-04100-5.25-5.25-5.25
2025Q3E2024-09-03100-5.25-5.25-5.25
2025Q3E2024-09-02100-5.25-5.25-5.25
2025Q3E2024-09-01100-5.25-5.25-5.25
2025Q3E2024-08-31100-5.25-5.25-5.25
2025Q3E2024-08-30100-5.25-5.25-5.25
2025Q3E2024-08-29100-5.25-5.25-5.25
2025Q3E2024-08-28100-5.25-5.25-5.25
2025Q3E2024-08-27100-5.25-5.25-5.25
2025Q3E2024-08-26100-5.25-5.25-5.25
2025Q3E2024-08-25100-5.25-5.25-5.25
2025Q3E2024-08-24100-5.25-5.25-5.25

Estimate history

EPS, annual-675000.001-736974.001-16414.2-10737.99-18664.11-2340.277-1455.529-228.476-36.244-16.46
Period201720182019202020212022202320242025TTM
EPS, quarterly-44.582-43.103-57.802-14.584-11.646-10.813-3.806-1.082-0.759
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual48.59442.99800000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0000.0010.0040.0120.0150.0561.0623.936
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0440.050.0560.2060.2520.5181.0621.8883.936
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.0043.00
Cost of Goods Sold Incl. D&A0.150.200.340.410.440.680.120.0036.92
Gross Profit-0.15-0.20-0.34-0.41-0.44-0.68-0.120.006.08
Selling, General and Administrative Excl. Other8.578.579.2916.0419.5325.265.502.3010.79
Research and Development2.482.782.847.258.034.790.170.00-
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-8.73-8.77-9.63-16.45-19.96-25.94-5.62-2.30-4.71
Interest Expense-0.000.000.000.010.010.450.080.73
Unusual Expense0.000.00-0.050.82-0.0130.480.000.035.19
Net Income Before Taxes-8.73-8.77-9.57-17.26-19.96-56.43-6.86-2.41-10.55
Income Taxes0.000.000.010.03-1.49-7.450.000.006.35
Consolidated Net Income-8.73-8.77-9.57-17.29-18.47-48.98-6.86-2.41-16.90
Net Income From Continuing Operations-8.73-8.77-9.57-17.31-18.50-48.98-6.86-2.41-16.90
Net Income-12.09-12.13-9.57-17.46-18.80-48.98-6.86-2.41-19.48
EPS (Recurring)-3.03-36.24-229.24-1,407.79-2,341.09-10,534.22-10,737.99-16,260.17-599,473.00
EPS (Basic, Before Extraordinaries)-16.46-36.24-228.48-1,455.53-2,340.28-18,664.11-10,737.99-16,414.20-736,974.00
EPS (Diluted)-16.46-36.24-228.48-1,455.53-2,340.28-18,664.11-10,737.99-16,414.20-736,974.00
EBITDA-8.57-8.57-9.29-16.04-19.53-25.26-5.50-2.30-1.81
Non-Operating Income (Expense)0.000.000.020.000.000.00-0.800.000.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.440.651.171.581.919.201.980.540.95
Price To Sales Ratio-------0.120.10
Gross Margin--------14.14
Operating Margin---------10.97
Net Margin---------45.31
Shares Outstanding3.941.060.060.020.010.000.000.000.00
Market Capitalization6.766.763.642.844.3230.306.115.707.38

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.040.040.040.040.080.080.08
Gross Profit-0.04-0.04-0.04-0.04-0.04-0.08-0.08-0.08
Selling, General and Administrative Excl. Other2.991.602.151.832.482.113.092.00
Research and Development1.360.350.370.401.260.751.100.76
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.03-1.63-2.19-1.87-2.52-2.19-3.17-2.08
Interest Expense0.000.000.00-0.000.000.000.00
Unusual Expense0.000.000.000.000.000.00-0.010.00
Net Income Before Taxes-3.03-1.63-2.19-1.87-2.52-2.18-3.15-2.08
Income Taxes0.000.000.000.000.000.000.010.00
Consolidated Net Income-3.03-1.63-2.19-1.87-2.52-2.18-3.15-2.08
Net Income From Continuing Operations-3.03-1.63-2.19-1.87-2.52-2.18-3.15-2.08
Net Income-3.03-1.63-4.04-3.39-2.52-2.18-3.15-2.08
EPS (Recurring)-0.76-1.08-3.81-10.81-11.65-14.58-57.89-43.09
EPS (Basic, Before Extraordinaries)-0.76-1.08-3.81-10.81-11.65-14.58-57.80-43.10
EPS (Diluted)-0.76-1.08-3.81-10.81-11.65-14.58-57.80-43.10
EBITDA-2.99-1.60-2.15-1.83-2.48-2.11-3.09-2.00
Non-Operating Income (Expense)0.000.000.000.00-0.000.000.02-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.090.060.190.210.190.300.37
Shares Outstanding3.941.891.060.520.250.210.060.05
Market Capitalization6.763.662.173.983.663.443.644.26

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.682.242.2917.7217.361.580.041.374.88
Short Term Receivables0.000.000.220.000.000.000.007.878.84
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.220.490.500.710.380.700.070.820.92
Total Current Assets4.892.733.0118.4317.742.280.1110.0614.64
Net Property, Plant & Equipment0.160.310.510.740.470.000.000.060.10
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable-0.001.82------
Intangible Assets0.000.040.210.388.511.820.0019.5131.37
Deferred Tax Assets------0.010.016.09
Other Assets0.040.000.570.000.000.000.000.000.00
Total Assets5.103.086.1219.5526.724.100.1129.6452.20
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.060.110.000.745.214.80
Accounts Payable0.580.521.220.460.680.000.004.385.32
Income Tax Payable0.090.26----0.650.35-
Other Current Liabilities0.250.711.123.471.290.681.184.7520.24
Total Current Liabilities0.921.492.344.002.080.681.9214.6930.37
Long Term Debt0.000.000.000.000.070.000.000.002.38
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities----1.61----
Other Liabilities0.000.000.000.000.650.000.004.190.00
Total Liabilities0.921.492.344.004.410.681.9218.8832.75
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.030.000.000.00
Common Equity4.181.593.7714.6722.313.38-1.8110.7519.44
Total Shareholders Equity4.181.593.7714.6722.313.42-1.8110.7619.45
Accumulated Minority Interest0.000.000.000.890.000.000.000.000.00
Total Equity4.181.593.7715.5622.313.42-1.8110.7619.45
Total Liabilities & Stockholders Equity5.103.086.1219.5526.724.100.1129.6452.20
Book Value Per Share3.9428.19247.991,270.746,162.143,015.91-12,296.56228,670.02963,496.29
Tangible Book Value Per Share3.9427.44234.131,237.863,810.771,395.38-12,296.56-186,104.12-590,853.53
Full-Time Employees65725243397390417
Price to Book Ratio0.742.291.160.191.360.460.540.694.03
Return on Assets-214.51-208.15-134.87-79.98-317.87-47.18-16.21-41.30-19.79
Return on Equity-304.04-356.82-187.69-100.08-380.82-97.81-53.88-111.88-58.34
Return on Invested Capital-209.98-601.14-458.69-126.12-218.89-200.98--157.05-41.57
Quick Ratio5.331.841.294.618.513.350.060.680.48
Current Ratio5.331.841.294.618.513.350.060.680.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-8.73-8.77-9.57-17.29-18.47-48.98-6.86-2.41-16.90
Depreciation0.150.200.340.410.440.680.120.002.90
Other Funds (Non Cash)0.560.731.932.961.1135.653.220.746.11
Funds from Operations-8.01-7.85-7.30-13.92-16.93-12.64-3.52-1.67-1.54
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.55-0.30-0.42-0.17-0.221.19-0.371.02-1.03
Cash from Operating Activities-8.56-8.14-7.73-14.09-17.15-11.46-3.89-0.65-2.57
Capital Expenditures0.000.000.00-0.01-0.58-0.86-0.040.00-
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.020.963.060.000.000.01
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00-3.65
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.010.372.19-0.040.00-3.64
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock14.0510.587.67-1.0517.2224.903.860.006.33
Repurchase of Common Pref Stock0.000.000.00-1.050.000.000.000.000.00
Sale of Common Pref Stock14.0510.587.670.0017.2224.903.860.006.33
Proceedsfrom Stock Options-4.820.003.190.000.000.003.860.006.33
Issuance or Reduction of Debt, Net0.000.000.000.000.000.001.670.54-1.98
Change in Long Term Debt0.000.000.000.000.000.000.000.00-1.98
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-1.98
Net Financing Active Other Cash Flow-0.020.000.00-0.290.000.000.000.02-1.66
Other Financing Activities Uses-0.020.000.00-0.290.000.000.000.00-1.66
Cash from Financing Activities14.0310.587.67-1.3417.2224.905.530.562.69
Exchange Rate Effect-0.02-0.000.01-0.01-0.080.14-0.060.02-
Net Change in Cash5.452.44-0.05-15.440.3715.781.53-0.07-3.51
Free Cash Flow-8.56-8.14-7.73-14.10-17.73-11.65-3.89-0.65-
Preferred Dividends (Cash Flow)--0.00--0.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.006.35

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments8.304.914.683.762.854.29
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.500.470.220.370.460.54
Total Current Assets8.795.384.894.133.314.83
Net Property, Plant & Equipment0.080.120.160.200.240.27
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.070.030.040.030.000.00
Total Assets8.945.525.104.363.555.10
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.680.280.580.681.040.67
Income Tax Payable0.030.060.090.000.000.01
Other Current Liabilities0.150.120.250.220.320.51
Total Current Liabilities0.860.460.920.911.361.18
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.860.460.920.911.361.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity8.085.064.183.462.183.92
Total Shareholders Equity8.085.064.183.462.183.92
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity8.085.064.183.462.183.92
Total Liabilities & Stockholders Equity8.945.525.104.363.555.10
Book Value Per Share2.052.683.946.678.6619.02
Tangible Book Value Per Share2.052.683.946.678.6619.02
Full-Time Employees--6---
Price to Book Ratio0.740.490.541.151.680.88
Return on Assets-139.75-154.76-214.51-212.68-207.14-133.36
Return on Equity-170.04-183.12-304.04-262.78-261.96-178.91
Return on Invested Capital-37.46-32.28-52.52-54.21-115.31-55.77
Quick Ratio10.2111.675.334.562.434.08
Current Ratio10.2111.675.334.562.434.08

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.03-1.63-2.19-1.87-2.52-2.18
Depreciation0.040.040.040.040.040.08
Other Funds (Non Cash)0.130.110.270.060.210.19
Funds from Operations-2.87-1.49-1.88-1.78-2.27-1.91
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.42-0.770.10-0.300.38-0.48
Cash from Operating Activities-2.44-2.26-1.78-2.07-1.89-2.39
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.00--0.000.00
Change in Capital Stock5.862.502.692.990.454.45
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.862.502.692.990.454.45
Proceedsfrom Stock Options0.000.00-5.881.060.454.37
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.020.000.000.000.000.00
Other Financing Activities Uses-0.020.000.000.000.000.00
Cash from Financing Activities5.842.502.692.990.454.45
Exchange Rate Effect-0.01-0.020.02-0.01-0.00-0.00
Net Change in Cash3.390.230.920.91-1.442.05
Free Cash Flow-2.44-2.26-1.78-2.07-1.89-2.39

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.45%0.0M4.4M85.64K
2026-10-150.88%0.0M4.4M104.60K
2026-09-300.35%0.0M4.4M105.67K
2026-09-150.52%0.0M4.4M116.02K
2026-08-310.29%0.0M4.4M157.13K
2026-08-140.39%0.0M4.4M162.67K
2026-07-310.53%0.0M3.6M213.70K
2026-07-150.51%0.0M3.6M3.93M
2026-06-300.43%0.0M3.6M3.86M
2026-06-151.28%0.0M3.6M3.78M
2026-05-290.75%0.0M3.6M3.80M
2026-05-153.27%0.1M3.6M4.08M
2026-04-3052.15%0.9M1.7M4.08M
2026-04-153.89%0.1M1.6M358.62K
2026-03-314.65%0.1M1.5M361.67K
2026-03-138.39%0.1M1.1M374.16K
2026-02-2710.57%0.1M1.1M1.01M
2026-02-135.54%0.1M1.1M700.07K
2026-01-3010.34%0.1M0.8M726.93K
2026-01-157.78%0.1M0.9M711.28K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-03SCHEDULE 13GSEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-06-098-KCurrent report2026-06-09SEC
2026-06-09424B5SEC
2026-06-098-KCurrent report2026-06-08SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-01S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-298-KCurrent report2026-05-22SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-04DNotice of sales of securities on Form D (Regulation D)SEC
2026-04-308-KCurrent report2026-04-30SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29EFFECTEffectiveness filing by commission orderSEC
2026-04-29424B3SEC
2026-04-28CORRESPSEC
2026-04-27UPLOADUpload SubmissionSEC
2026-04-23S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Sio Capital Management, LLC4.89%
Ikarian Capital, LLC2.72%
AdvisorShares Investments LLC0.98%
RENAISSANCE TECHNOLOGIES LLC0.87%
ARMISTICE CAPITAL, LLC0.87%
BOOTHBAY FUND MANAGEMENT, LLC0.82%
StoneX Group Inc.0.63%
XTX Topco Ltd0.52%
HRT FINANCIAL LP0.42%
VANGUARD CAPITAL MANAGEMENT LLC0.41%

Funds

Fund% owned
AdvisorShares Psychedelics ETF0.96%
VANGUARD EXTENDED MARKET INDEX FUND0.41%
Fidelity Extended Market Index Fund0.39%
Fidelity Nasdaq Composite Index Fund0.02%

OakChart. ENVB. Cached 15 minutes.

Some panels did not load: ratings, insider.